Clinical Trial

Placental Progesterone Membrane Receptors in Fetal Growth Restriction

Completed
View on ClinicalTrials.gov →
Summary
This prospective observational case-control study aims to compare placental expression levels of progesterone membrane receptors, including PGRMC1, PGRMC2, and PAQR family receptors, among pregnancies affected by impaired fetal growth and appropriately grown control pregnancies. Pregnancies with suspected impaired fetal growth were phenotypically classified before biomarker analyses according to the contemporary Delphi consensus and ISUOG diagnostic criteria into fetal growth restriction (FGR) and small for gestational age (SGA). Placental tissue samples obtained at delivery were analyzed using quantitative real-time polymerase chain reaction (qRT-PCR). The final study cohort comprised 110 singleton pregnancies, including 48 FGR, 29 SGA, and 33 appropriately grown controls. The study also evaluated the association between progesterone membrane receptor expression and adverse perinatal outcomes.
Protocol Amendment History 6 changes
critical Trial completed 2026-08-08
critical Primary endpoint(s) modified 2026-08-08
notable Enrollment increased: 90 -> 110 participants 2026-08-08
minor Trial arms changed: 2 -> 3 2026-08-08
notable Primary completion moved earlier: 2027-01 -> 2026-07-20 2026-08-08
minor Completion moved earlier: 2027-01 -> 2026-07-20 2026-08-08
Trial Details
NCT Number NCT07701837
Lead Sponsor Samsun University
Conditions Fetal Growth Restriction, Placenta, Progesterone Membrane Receptor, PGRMC1, PGRMC2, Placental Dysfunction, Pregnancy
Enrollment 110 participants
Start Date 2025-08-01
Primary Completion 2026-07-20 (estimated)
Study Completion 2026-07-20 (estimated)
Updated on ClinicalTrials.gov 2026-08-07